流式细胞术检测的微小残留病水平可为成人T细胞急性淋巴细胞白血病提供可靠的风险分层
该回顾性研究纳入94例成人T-ALL患者,采用六至八色流式细胞术检测诱导结束时的微小残留病(EOI-MRD)。EOI-MRD阳性患者复发累积发生率更高、无复发生存和总生存更低,且在多变量分析中EOI-MRD是复发和生存的独立预后因素。对于首次缓解后接受异基因造血干细胞移植的患者,EOI-MRD阳性可预测移植后复发。
要点
- EOI-MRD阳性成人T-ALL患者复发风险显著增高、生存显著降低。
- EOI-MRD是多变量分析中复发和生存的独立预后因素。
- 首次缓解后接受allo-HSCT者,EOI-MRD阳性可预测移植后复发。
核心结论
- 基于流式细胞术的EOI-MRD是成人T-ALL复发和生存的独立预后因素。
- 对于接受HSCT的患者,EOI-MRD可用于识别allo-HSCT后高复发风险的患者。
研究设计与样本
- 回顾性研究,纳入94例成人T-ALL患者。
- 采用六至八色流式细胞术检测诱导结束时的微小残留病(EOI-MRD)。
临床怎么用
- 在成人T-ALL诱导结束时采用流式细胞术检测MRD,用于风险分层。
- EOI-MRD阳性患者可考虑视为高复发风险,尤其在计划接受allo-HSCT时。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minimal residual disease (MRD) is an important independent prognostic factor for relapse and survival in acute lymphoblastic leukaemia (ALL). Compared with adult B-cell ALL, reports of adult T-cell ALL (T-ALL) MRD have been scarce and mostly based on molecular methods. We evaluated the prognostic value of multiparameter flow cytometry (FCM)-based MRD at the end of induction (EOI-MRD). The present retrospective study included 94 adult patients with T-ALL. MRD was detected by six- to eight-colour FCM. Patients who were EOI-MRD positive had a higher cumulative incidence of relapse (CIR) (87·6% vs. 38·8%, P = 0·0020), and a lower relapse-free survival (RFS) (5·4% vs. 61·0%, P = 0·0005) and overall survival (OS) (32·7% vs. 69·7%, P < 0·0001) than those who were EOI-MRD negative. Moreover, for patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) at their first remission, EOI-MRD positivity was predictive of post-transplant relapse (2-year CIR: 68·2% vs. 4·0%, P = 0·0003). Multivariate analysis showed that EOI-MRD was an independent prognostic factor for CIR [hazard ratio (HR) 2·139, P = 0·046], RFS (HR 2·125, P = 0·048) and OS (HR 2·987, P = 0·017). In conclusion, EOI-MRD based on FCM was an independent prognostic factor for relapse and survival in adult T-ALL. For patients who underwent HSCT, EOI-MRD could be used to identify patients with a high risk of relapse after allo-HSCT.
引用
- Wang H, Zhou Y, Huang X, et al. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia. Br J Haematol. 2021. PMID: 33764511. doi:10.1111/bjh.17424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。